Episurf Medical Sales in line with expectations - DNB

Episurf Medical’s Q1 sales were broadly in line with our estimate, while operating expenses were slightly higher than we expected. For the US market, the company has signed several distribution agreements for its first product, and we see several more agreements in the coming quarters. We reiterate our fair value of SEK3.3–9.3.

Länk till analysen i sin helhet: https://www.dnb.no/seg-fundamental/fundamentalweb/GetReportSpon.aspx?file=CMPSP_214395.pdf